Rieveschl NB, Song W, Li A, et al. - In patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD), researchers desired to know how baseline macular atrophy (MA) influences visual acuity (VA). Based on baseline spectral-domain optical coherence tomography image findings, participants were grouped into three cohorts: foveal MA, nonfoveal MA, and no MA. Outcomes were assessed at 1, 2, and 3 years following anti-VEGF therapy. After adjusting for baseline lesion sizes at 3 years, no differences existed in MA growth between eyes with foveal and nonfoveal MA. The presence of baseline foveal MA was liked to significant vision loss in individuals with nAMD receiving anti-VEGF in routine clinical practice.